2 studies found for:    23177515 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Condition: GIST
Intervention: Drug: ponatinib
2 Active, not recruiting
Has Results
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Regorafenib (Stivarga, BAY73-4506);   Drug: Placebo;   Drug: Best supportive care

Indicates status has not been verified in more than two years